Frazier Life Sciences Management, L.P. Passage Bio, Inc. Transaction History

Frazier Life Sciences Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.66 - $1.01 $60,575 - $92,698	-91,781 Reduced 4.96%	1,758,219 $1.16 Million
Q2 2023 Aug 14, 2023	SELL	$0.82 - $1.19 $1.56 Million - $2.27 Million	-1,906,915 Reduced 50.76%	1,850,000 $1.74 Million
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $1.53 Million - $3.11 Million	-1,252,304 Reduced 25.0%	3,756,915 $4.7 Million
Q1 2022 May 16, 2022	BUY	$2.66 - $6.49 $13.3 Million - $32.5 Million	5,009,219 New	5,009,219 $15.5 Million

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $28.3M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.